← Back to Clinical Trials
Recruiting NCT06356831

NCT06356831 National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06356831
Status Recruiting
Phase
Sponsor Centre Hospitalier Intercommunal Creteil
Condition Endometriosis
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-06-15
Primary Completion 2027-07-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-06-15 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

National multicentric registry of a cohort of patient with suffering parietal endometriosis, carried out by a multidisciplinary radiosurgery team

Eligibility Criteria

Inclusion Criteria: * Presence of parietal endometriosis: with suggestive clinical and imaging criteria (MRI and ultrasound) * Symptomatic parietal endometriosis (VAS \> 3 OR bothersome bleeding OR reported impact on quality of life) Exclusion Criteria: * Endometriosis not affecting the anterior wall of the abdomen (as deep pelvic muscle: ilio-psoas, obturators, perineal, ischio-anal fossa) * Minor patient (\< 18 years) * Pregnant patient at any trimester * Patient with hemostasis disorders (constitutional or acquired) * Patient with systemic infection or localized scar infection upon inclusion. * Patient with contraindications to MRI * Female patient with a planned medical or surgical procedure for the duration of the study that may interfere with the proper conduct of the study. * Patient unable to understand the information provided * Patient who is not affiliated to the social security system * Patient under curatorship or tutorship * Patient with a nodule of primary or secondary malignant tumor origin

Contact & Investigator

Central Contact

Léo Razakamanantsoa, Dr

✉ Leo.Razakamanantsoa@chicreteil.fr

📞 0157023567

Principal Investigator

Léo RAZAKAMAMANTSOA

PRINCIPAL INVESTIGATOR

CHIC

Frequently Asked Questions

Who can join the NCT06356831 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Endometriosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06356831 currently recruiting?

Yes, NCT06356831 is actively recruiting participants. Contact the research team at Leo.Razakamanantsoa@chicreteil.fr for enrollment information.

Where is the NCT06356831 trial being conducted?

This trial is being conducted at Bordeau, France, Bordeaux, France, Clermont-Ferrand, France, Créteil, France and 11 additional locations.

Who is sponsoring the NCT06356831 clinical trial?

NCT06356831 is sponsored by Centre Hospitalier Intercommunal Creteil. The principal investigator is Léo RAZAKAMAMANTSOA at CHIC. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology